Optimizing IBS Management through Accurate Disease Assessment and Improved Treatment Selection

Release date: June 27, 2019
Expiration date: June 27, 2020
Estimated time to complete activity: 1.0 hour(s)

 

FACULTY

Brian E. Lacy, PhD, MD
Professor of Medicine
Senior Associate Consultant
Mayo Clinic, Jacksonville
Jacksonville, Florida

PROGRAM OVERVIEW

Suboptimal irritable bowel syndrome (IBS) management frequently results from delayed diagnosis, underappreciation of disease impact on the part of providers, and inadequate symptom control despite therapy. There is a strong need for clinician education on strategies to promote more accurate disease assessment and improved treatment selection. In addition, clinicians also face challenges related to the need to keep pace with developments in understanding of the disease. For example, although recognition of the role of dysbiosis in IBS pathogenesis has grown significantly in recent years, the place of therapies targeting the gut microbiota has yet to be firmly established. Presently, several studies to address this issue are ongoing. As the results of these investigations become available, clinicians will require detailed education, along with expert guidance, to determine how to incorporate these findings into their therapeutic decision-making.

TARGET AUDIENCE

This educational initiative has been designed for internal medicine physicians, nurse practitioners, physician assistants, and gastroenterology nurses involved in the management of patients with IBS.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Apply an approach to the diagnosis of IBS that is consistent with current evidence-based guidelines
  • Utilize best practices for the management of IBS, including accurate assessment of disease impact and selection of effective therapy
  • Describe current evidence in support of the gut microbiota as a therapeutic target in IBS treatment
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 27, 2019 through June 27, 2020 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Brian E. Lacy, PhD, MD
Advisory Boards: Ironwood, Salix Pharmaceuticals, Inc., Shire
Consulting Fees: Neurogastrix, Urovant, Viver

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Salix Pharmaceuticals, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Salix Pharmaceuticals, Inc.

Continue to Pretest